Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

138.60DKK
1:00pm BST
Change (% chg)

kr.1.35 (+0.98%)
Prev Close
kr.137.25
Open
kr.139.55
Day's High
kr.139.75
Day's Low
kr.138.25
Volume
68,227
Avg. Vol
155,728
52-wk High
kr.214.80
52-wk Low
kr.117.75

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic Appoints Henrik Juuel As CFO
Thursday, 31 May 2018 

May 31 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC ANNOUNCES APPOINTMENT OF HENRIK JUUEL AS CHIEF FINANCIAL OFFICER.APPOINTMENT OF HENRIK JUUEL TO POSITION OF EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER..HENRIK JUUEL PLANS TO JOIN BAVARIAN NORDIC IN Q4 OF 2018..  Full Article

Bavarian Nordic FY EBIT Rises To DKK 353.2‍​ Million
Monday, 12 Mar 2018 

March 12 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC ANNOUNCES ANNUAL REPORT 2017.FY EBIT DKK 353.2‍​ MILLION VERSUS DKK 33.0 MILLION YEAR AGO.FY REVENUE DKK ‍REVENUE 1.37 BILLION VERSUS DKK 1.01 BILLION YEAR AGO.IN 2018 EXPECTS REVENUES OF APPROXIMATELY DKK 500 MILLION‍​.IN 2018 EXPECTS LOSS BEFORE INTEREST AND TAX (EBIT) OF APPROXIMATELY DKK 385 MILLION.  Full Article

Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer
Thursday, 8 Mar 2018 

March 8 (Reuters) - Bavarian Nordic A/S ::BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER.BAVARIAN NORDIC A/S - CO, ‍BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL​.BAVARIAN NORDIC A/S - ‍PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS​.  Full Article

Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS.‍BAVARIAN NORDIC AND ASTRAZENECA WILL CONTRIBUTE CLINICAL TRIAL MATERIAL AND PROVIDE FINANCIAL SUPPORT FOR PHASE 1/2​.‍NEW COLLABORATION THAT WILL INVESTIGATE CV301 AND DURVALUMAB (IMFINZI(TM))​.  Full Article

Bavarian Nordic Announces Planned Departure Of CFO Ole Larsen
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Bavarian Nordic A/S ::BAVARIAN NORDIC ANNOUNCES THE PLANNED DEPARTURE OF CHIEF FINANCIAL OFFICER, OLE LARSEN.PLANNED TRANSITION OF CFO WILL TAKE PLACE WITHIN 2018 ONCE AN APPROPRIATE CANDIDATE HAS BEEN IDENTIFIED.INITIATING A SEARCH FOR THE POSITION OF CHIEF FINANCIAL OFFICER.  Full Article

‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Bavarian Nordic A/S ::‍BAVARIAN NORDIC ANNOUNCES EXERCISE OF CLINICAL OPTION BY US GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE​.BAVARIAN NORDIC A/S SAYS ‍CONTRACT OPTION IS EXPECTED TO BE REVENUE RECOGNIZED BETWEEN 2018 AND 2022​.BAVARIAN NORDIC- OPTION, WHICH REPRESENTS ABOUT $37 MILLION OF TOTAL CONTRACT OF UP TO $539 MILLION, WILL COVER DEVELOPMENT COSTS ASSOCIATED WITH PHASE 3 STUDY​.ANNOUNCEMENT DOES NOT AFFECT COMPANY'S EXPECTATIONS FOR FINANCIAL RESULTS FOR 2017​.  Full Article

Bavarian Nordic Q3 EBIT at DKK 432 million
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BAVARIAN NORDIC A/S ::‍OUTLOOK FOR 2017 MAINTAINED​.Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO.Q3 REVENUE DKK 734.3‍​ MILLION VERSUS DKK 452.3 MILLION YEAR AGO.  Full Article

Bavarian Nordic provides update on its RSV vaccine
Thursday, 21 Sep 2017 

Sept 21 (Reuters) - BAVARIAN NORDIC A/S ::REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE.SAYS ‍RANDOMIZED, PLACEBO-CONTROLLED TRIAL, EVALUATED SAFETY, TOLERABILITY AND IMMUNOGENICITY OF RECOMBINANT VACCINE IN 421 HEALTHY ADULTS AGED 55 AND OLDER​.‍WILL PARTNER WITH A GLOBAL CRO TO DEVELOP A NOVEL AND DIFFERENTIATED APPROACH TO RSV CHALLENGE MODEL​.‍AT 6 MONTH FOLLOW UP, A PERSISTENT ANTIBODY RESPONSE AGAINST MULTIPLE RSV TARGETS CAN STILL BE OBSERVED​.  Full Article

Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Bavarian Nordic A/S - :Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer.An independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile.Contents of this announcement do not affect the company's expectations for the financial results for 2017.  Full Article

Bavarian Q2 EBIT at DKK 102.3 million
Friday, 25 Aug 2017 

Aug 25 (Reuters) - BAVARIAN NORDIC A/S ::‍MAINTAINS ITS FINANCIAL EXPECTATIONS FOR 2017​.Q2 REVENUE DKK 397.3‍​ MILLION VERSUS DKK 116.6 MILLION YEAR AGO.Q2 EBIT DKK 102.3 ‍​ MILLION VERSUS LOSS DKK 54.0 MILLION YEAR AGO.  Full Article